Focal Segmental Glomerulosclerosis  >>  pamrevlumab (FG-3019)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pamrevlumab (FG-3019) / FibroGen
NCT00782561: Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

Terminated
1
2
US
FG-3019
FibroGen
Focal Segmental Glomerulosclerosis
06/09
06/09

Download Options